drugset
drugset / Trial / NCT04236310

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

NCT04236310 ↗

Phase 2 Unknown 37 enrolled Ruijin Hospital Jiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of the SHR6390 in combination with anastrozole, pyrotinib, and trastuzumab in patients with ER-positive, HER2-positive breast cancer in the neoadjuvant setting.

Timeline

Start
2020-01-15
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalpiciclib Small molecule 150 mg Oral
Background Anastrozole Other / unclassified 1 unknown Oral
Background Pyrotinib Small molecule 400 mg —
Background Trastuzumab Monoclonal antibody 6 mg/kg Other

Indications

HER2 positive breast carcinoma estrogen-receptor positive breast cancer